Patients are bracing for “D-Day,” the date their insurance coverage firms will cease overlaying the medicine. Docs are getting letters from insurance coverage investigators discouraging new prescriptions. And pharmacies are being advised by insurers to test for a selected analysis when filling prescriptions.
It’s a cost on all fronts by insurance coverage firms to comprise the spiraling prices of a brand new class of weight loss-inducing medicine, the GLP-1s.
A few of these therapies — like Novo Nordisk’s Wegovy — are authorized for weight problems, whereas others — like Novo’s Ozempic and Eli Lilly’s Mounjaro — are authorized for diabetes, however all of them make use of related mechanisms and have exploded in demand for his or her capacity to curb urge for food and lower important quantities of weight.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
GET STARTED